查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1742557

过敏反应市场－全球产业分析、规模、份额、成长、趋势及预测（2025-2035）

Anaphylaxis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 214 Pages | 商品交期: 2-10个工作天内

价格

过敏反应市场 - 报告范围

TMR 的全球过敏性休克市场报告研究了过去和当前的成长趋势及机会，旨在深入了解 2025 年至 2035 年预测期内的市场指标。该报告提供了 2019 年至 2035 年期间全球过敏性休克市场的收入，以 2025 年为基准年，2035 年为预测年。报告中也提供了 2025 年至 2035 年全球过敏性休克市场的年复合成长率(CAGR%)。

本报告经过广泛调查后编写。主要研究工作包括：分析师对关键意见领袖、产业领导者和舆论领袖进行访谈。次要研究则参考了主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解过敏反应市场。

市场概况
2024 年的市场价值 21亿美元
2035年的市场价值 39亿美元
复合年增长率 5.9%

本报告深入探讨了全球过敏性休克市场的竞争格局。该报告确定了全球过敏性休克市场的主要参与者，并根据不同特征对每家公司进行了分析。本报告对全球过敏性休克市场参与者的分析涵盖了公司概况、财务状况、近期发展和 SWOT 分析。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2035年全球过敏反应市场分析与预测

第五章：关键见解

  • 主要地区/国家的医疗保健支出
  • 过敏反应管理的技术进步
  • 重点地区/国家的流行病学
  • 主要地区/国家的监管情况
  • 波特五力分析
  • PESTEL分析
  • 价值链分析
  • 最终用户的关键购买指标
  • 新市场进入者的市场进入策略
  • 重要产业事件（合作伙伴关係、协作、产品审批、併购）
  • 对主要竞争对手提供的产品基准化分析

第六章：全球市场分析与预测：依药品类别

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2035 年药品类别市值预测
    • 肾上腺素
    • 抗组织胺药
    • 其他的
  • 各药品类别的市场吸引力

第七章：全球市场分析与预测：按剂型

  • 介绍和定义
  • 主要发现/进展
  • 2020 年至 2035 年按剂型分類的市场价值预测
    • 注射剂
    • 片剂/胶囊
    • 其他的
  • 不同剂型的市场吸引力

第八章：全球市场分析与预测：依管理途径

  • 介绍和定义
  • 主要发现/进展
  • 2020 年至 2035 年按给药途径分類的市场价值预测
    • 肌肉注射
    • 皮下注射
    • 口服
    • 其他的
  • 按给药途径分類的市场吸引力

第九章：全球市场分析与预测：依药物类型

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2035 年药品市场价值预测
    • 品牌
    • 通用的
  • 不同药物类型的市场吸引力

第十章：全球市场分析与预测：按配销通路

  • 介绍和定义
  • 主要发现/进展
  • 2020-2035年配销通路市场价值预测
    • 医院药房
    • 零售药局
    • 网路药局
  • 配销通路的市场吸引力

第 11 章：全球市场分析与预测：按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 各地区市场吸引力

第十二章：北美市场分析与预测

  • 我们
  • 加拿大

第十三章：欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
  • 中国
  • 日本
  • 印度
  • 澳洲和纽西兰
  • 亚太其他地区

第十五章：拉丁美洲市场分析与预测

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第十六章：中东和非洲市场分析与预测

  • 海湾合作委员会国家
  • 南非
  • 中东和非洲其他地区

第 17 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 各公司市占率分析（2024 年）
  • 公司简介
    • Viatris Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Fresenius Kabi AG
    • Kaleo, Inc.
    • ARS Pharmaceuticals, Inc.
    • Mylan NV
    • Glenmark Pharmaceuticals
    • Bryn Pharma
    • Aquestive Therapeutics, Inc.
    • Endo, Inc.
    • DMK Pharmaceuticals Corporation
    • ALK-Abello A/S
    • Amneal Pharmaceuticals LLC
    • Grand Pharma (China) Co., Ltd.
Product Code: TMRGL86653

Anaphylaxis Market - Scope of Report

TMR's report on the global anaphylaxis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global anaphylaxis market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anaphylaxis market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anaphylaxis market.

Market Snapshot
Market Value in 2024US$ 2.1 Bn
Market Value in 2035US$ 3.9 Bn
CAGR5.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anaphylaxis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anaphylaxis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anaphylaxis market.

The report delves into the competitive landscape of the global anaphylaxis market. Key players operating in the global anaphylaxis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anaphylaxis market profiled in this report.

Key Questions Answered in global anaphylaxis Market Report:

  • What is the sales/revenue generated by anaphylaxis across all regions during the forecast period?
  • What are the opportunities in the global anaphylaxis market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Anaphylaxis Market - Research Objectives and Research Approach

The comprehensive report on the global anaphylaxis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anaphylaxis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anaphylaxis market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anaphylaxis Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anaphylaxis Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Healthcare Expenditure across Key Regions / Countries
  • 5.2. Technological Advancements in Anaphylaxis Management
  • 5.3. Epidemiology of Anaphylaxis across Key Regions / Countries
  • 5.4. Regulatory Scenario across Key Regions / Countries
  • 5.5. PORTER's Five Forces Analysis
  • 5.6. PESTEL Analysis
  • 5.7. Value Chain Analysis
  • 5.8. Key Purchase Metrics for End-users
  • 5.9. Go-to-Market Strategy for New Market Entrants
  • 5.10. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
  • 5.11. Benchmarking of Products Offered by the Leading Competitors

6. Global Anaphylaxis Market Analysis and Forecasts, By Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Class, 2020-2035
    • 6.3.1. Epinephrine
    • 6.3.2. Antihistamines
    • 6.3.3. Others
  • 6.4. Market Attractiveness By Drug Class

7. Global Anaphylaxis Market Analysis and Forecasts, By Dosage Form

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Dosage Form, 2020-2035
    • 7.3.1. Injectables
    • 7.3.2. Tablets / Capsules
    • 7.3.3. Others
  • 7.4. Market Attractiveness By Dosage Form

8. Global Anaphylaxis Market Analysis and Forecasts, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Route of Administration, 2020-2035
    • 8.3.1. Intramuscular Injection
    • 8.3.2. Subcutaneous Injection
    • 8.3.3. Oral
    • 8.3.4. Others
  • 8.4. Market Attractiveness By Route of Administration

9. Global Anaphylaxis Market Analysis and Forecasts, By Drug Type

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Drug Type, 2020-2035
    • 9.3.1. Branded
    • 9.3.2. Generic
  • 9.4. Market Attractiveness By Drug Type

10. Global Anaphylaxis Market Analysis and Forecasts, By Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness By Distribution Channel

11. Global Anaphylaxis Market Analysis and Forecasts, By Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast By Region
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness By Region

12. North America Anaphylaxis Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Class, 2020-2035
    • 12.2.1. Epinephrine
    • 12.2.2. Antihistamines
    • 12.2.3. Others
  • 12.3. Market Value Forecast By Dosage Form, 2020-2035
    • 12.3.1. Injectables
    • 12.3.2. Tablets / Capsules
    • 12.3.3. Others
  • 12.4. Market Value Forecast By Route of Administration, 2020-2035
    • 12.4.1. Intramuscular Injection
    • 12.4.2. Subcutaneous Injection
    • 12.4.3. Oral
    • 12.4.4. Others
  • 12.5. Market Value Forecast By Drug Type, 2020-2035
    • 12.5.1. Branded
    • 12.5.2. Generic
  • 12.6. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Value Forecast By Country, 2020-2035
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Drug Class
    • 12.8.2. By Dosage Form
    • 12.8.3. By Route of Administration
    • 12.8.4. By Drug Type
    • 12.8.5. By Distribution Channel
    • 12.8.6. By Country

13. Europe Anaphylaxis Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Class, 2020-2035
    • 13.2.1. Epinephrine
    • 13.2.2. Antihistamines
    • 13.2.3. Others
  • 13.3. Market Value Forecast By Dosage Form, 2020-2035
    • 13.3.1. Injectables
    • 13.3.2. Tablets / Capsules
    • 13.3.3. Others
  • 13.4. Market Value Forecast By Route of Administration, 2020-2035
    • 13.4.1. Intramuscular Injection
    • 13.4.2. Subcutaneous Injection
    • 13.4.3. Oral
    • 13.4.4. Others
  • 13.5. Market Value Forecast By Drug Type, 2020-2035
    • 13.5.1. Branded
    • 13.5.2. Generic
  • 13.6. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Value Forecast By Country / Sub-region, 2020-2035
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Spain
    • 13.7.5. Italy
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Drug Class
    • 13.8.2. By Dosage Form
    • 13.8.3. By Route of Administration
    • 13.8.4. By Drug Type
    • 13.8.5. By Distribution Channel
    • 13.8.6. By Country / Sub-region

14. Asia Pacific Anaphylaxis Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Class, 2020-2035
    • 14.2.1. Epinephrine
    • 14.2.2. Antihistamines
    • 14.2.3. Others
  • 14.3. Market Value Forecast By Dosage Form, 2020-2035
    • 14.3.1. Injectables
    • 14.3.2. Tablets / Capsules
    • 14.3.3. Others
  • 14.4. Market Value Forecast By Route of Administration, 2020-2035
    • 14.4.1. Intramuscular Injection
    • 14.4.2. Subcutaneous Injection
    • 14.4.3. Oral
    • 14.4.4. Others
  • 14.5. Market Value Forecast By Drug Type, 2020-2035
    • 14.5.1. Branded
    • 14.5.2. Generic
  • 14.6. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Value Forecast By Country / Sub-region, 2020-2035
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Drug Class
    • 14.8.2. By Dosage Form
    • 14.8.3. By Route of Administration
    • 14.8.4. By Drug Type
    • 14.8.5. By Distribution Channel
    • 14.8.6. By Country / Sub-region

15. Latin America Anaphylaxis Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Drug Class, 2020-2035
    • 15.2.1. Epinephrine
    • 15.2.2. Antihistamines
    • 15.2.3. Others
  • 15.3. Market Value Forecast By Dosage Form, 2020-2035
    • 15.3.1. Injectables
    • 15.3.2. Tablets / Capsules
    • 15.3.3. Others
  • 15.4. Market Value Forecast By Route of Administration, 2020-2035
    • 15.4.1. Intramuscular Injection
    • 15.4.2. Subcutaneous Injection
    • 15.4.3. Oral
    • 15.4.4. Others
  • 15.5. Market Value Forecast By Drug Type, 2020-2035
    • 15.5.1. Branded
    • 15.5.2. Generic
  • 15.6. Market Value Forecast By Distribution Channel, 2020-2035
    • 15.6.1. Hospital Pharmacies
    • 15.6.2. Retail Pharmacies
    • 15.6.3. Online Pharmacies
  • 15.7. Market Value Forecast By Country / Sub-region, 2020-2035
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Drug Class
    • 15.8.2. By Dosage Form
    • 15.8.3. By Route of Administration
    • 15.8.4. By Drug Type
    • 15.8.5. By Distribution Channel
    • 15.8.6. By Country / Sub-region

16. Middle East & Africa Anaphylaxis Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast By Drug Class, 2020-2035
    • 16.2.1. Epinephrine
    • 16.2.2. Antihistamines
    • 16.2.3. Others
  • 16.3. Market Value Forecast By Dosage Form, 2020-2035
    • 16.3.1. Injectables
    • 16.3.2. Tablets / Capsules
    • 16.3.3. Others
  • 16.4. Market Value Forecast By Route of Administration, 2020-2035
    • 16.4.1. Intramuscular Injection
    • 16.4.2. Subcutaneous Injection
    • 16.4.3. Oral
    • 16.4.4. Others
  • 16.5. Market Value Forecast By Drug Type, 2020-2035
    • 16.5.1. Branded
    • 16.5.2. Generic
  • 16.6. Market Value Forecast By Distribution Channel, 2020-2035
    • 16.6.1. Hospital Pharmacies
    • 16.6.2. Retail Pharmacies
    • 16.6.3. Online Pharmacies
  • 16.7. Market Value Forecast By Country / Sub-region, 2020-2035
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Drug Class
    • 16.8.2. By Dosage Form
    • 16.8.3. By Route of Administration
    • 16.8.4. By Drug Type
    • 16.8.5. By Distribution Channel
    • 16.8.6. By Country / Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis By Company (2024)
  • 17.3. Company Profiles
    • 17.3.1. Viatris Inc.
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. Pfizer Inc.
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. Teva Pharmaceutical Industries Ltd.
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Fresenius Kabi AG
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. Kaleo, Inc.
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. ARS Pharmaceuticals, Inc.
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. Mylan N.V.
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. Glenmark Pharmaceuticals
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Bryn Pharma
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. Aquestive Therapeutics, Inc.
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments
    • 17.3.11. Endo, Inc.
      • 17.3.11.1. Company Overview
      • 17.3.11.2. Financial Overview
      • 17.3.11.3. Product Portfolio
      • 17.3.11.4. Business Strategies
      • 17.3.11.5. Recent Developments
    • 17.3.12. DMK Pharmaceuticals Corporation
      • 17.3.12.1. Company Overview
      • 17.3.12.2. Financial Overview
      • 17.3.12.3. Product Portfolio
      • 17.3.12.4. Business Strategies
      • 17.3.12.5. Recent Developments
    • 17.3.13. ALK-Abello A/S
      • 17.3.13.1. Company Overview
      • 17.3.13.2. Financial Overview
      • 17.3.13.3. Product Portfolio
      • 17.3.13.4. Business Strategies
      • 17.3.13.5. Recent Developments
    • 17.3.14. Amneal Pharmaceuticals LLC
      • 17.3.14.1. Company Overview
      • 17.3.14.2. Financial Overview
      • 17.3.14.3. Product Portfolio
      • 17.3.14.4. Business Strategies
      • 17.3.14.5. Recent Developments
    • 17.3.15. Grand Pharma (China) Co., Ltd.
      • 17.3.15.1. Company Overview
      • 17.3.15.2. Financial Overview
      • 17.3.15.3. Product Portfolio
      • 17.3.15.4. Business Strategies
      • 17.3.15.5. Recent Developments

List of Tables

  • Table 01: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 02: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 03: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 04: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 05: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 06: Global Anaphylaxis Market Value (US$ Bn) Forecast, By Region, 2020-2035
  • Table 07: North America - Anaphylaxis Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 08: North America - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 09: North America - Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 10: North America - Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 11: North America - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 12: North America - Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 13: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
  • Table 14: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 15: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 16: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 17: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 18: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 19: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
  • Table 20: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 21: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 22: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 23: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 24: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 25: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
  • Table 26: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 27: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 28: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 29: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 30: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 31: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
  • Table 32: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Class, 2020-2035
  • Table 33: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, By Dosage Form, 2020-2035
  • Table 34: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2035
  • Table 35: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 36: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 02: Global Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 03: Global Anaphylaxis Market Revenue (US$ Bn), by Epinephrine, 2020-2035
  • Figure 04: Global Anaphylaxis Market Revenue (US$ Bn), by Antihistamines, 2020-2035
  • Figure 05: Global Anaphylaxis Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 06: Global Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 07: Global Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 08: Global Anaphylaxis Market Revenue (US$ Bn), by Injectables, 2020-2035
  • Figure 09: Global Anaphylaxis Market Revenue (US$ Bn), by Tablets / Capsules, 2020-2035
  • Figure 10: Global Anaphylaxis Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 11: Global Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 12: Global Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 13: Global Anaphylaxis Market Revenue (US$ Bn), by Intramuscular Injection, 2020-2035
  • Figure 14: Global Anaphylaxis Market Revenue (US$ Bn), by Subcutaneous Injection, 2020-2035
  • Figure 15: Global Anaphylaxis Market Revenue (US$ Bn), by Oral, 2020-2035
  • Figure 16: Global Anaphylaxis Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 17: Global Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 18: Global Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 19: Global Anaphylaxis Market Revenue (US$ Bn), by Branded, 2020-2035
  • Figure 20: Global Anaphylaxis Market Revenue (US$ Bn), by Generic, 2020-2035
  • Figure 21: Global Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 22: Global Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 23: Global Anaphylaxis Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
  • Figure 24: Global Anaphylaxis Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
  • Figure 25: Global Anaphylaxis Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
  • Figure 26: Global Anaphylaxis Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 27: Global Anaphylaxis Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 28: North America - Anaphylaxis Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 29: North America - Anaphylaxis Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 30: North America - Anaphylaxis Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 31: North America - Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 32: North America - Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 33: North America - Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 34: North America - Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 35: North America - Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 36: North America - Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 37: North America - Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 38: North America - Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 39: North America - Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 40: North America - Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 41: Europe - Anaphylaxis Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 42: Europe - Anaphylaxis Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 43: Europe - Anaphylaxis Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 44: Europe - Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 45: Europe - Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 46: Europe - Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 47: Europe - Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 48: Europe - Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 49: Europe - Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 50: Europe - Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 51: Europe - Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 52: Europe - Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 53: Europe - Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 54: Asia Pacific - Anaphylaxis Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 55: Asia Pacific - Anaphylaxis Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 56: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 57: Asia Pacific - Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 58: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 59: Asia Pacific - Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 60: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 61: Asia Pacific - Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 62: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 63: Asia Pacific - Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 64: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 65: Asia Pacific - Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 66: Asia Pacific - Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 67: Latin America - Anaphylaxis Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 68: Latin America - Anaphylaxis Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 69: Latin America - Anaphylaxis Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 70: Latin America - Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 71: Latin America - Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 72: Latin America - Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 73: Latin America - Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 74: Latin America - Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 75: Latin America - Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 76: Latin America - Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 77: Latin America - Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 78: Latin America - Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 79: Latin America - Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 80: Middle East & Africa - Anaphylaxis Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 81: Middle East & Africa - Anaphylaxis Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 82: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 83: Middle East & Africa - Anaphylaxis Market Value Share Analysis, By Drug Class, 2024 and 2035
  • Figure 84: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, By Drug Class, 2025-2035
  • Figure 85: Middle East & Africa - Anaphylaxis Market Value Share Analysis, By Dosage Form, 2024 and 2035
  • Figure 86: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, By Dosage Form, 2025-2035
  • Figure 87: Middle East & Africa - Anaphylaxis Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 88: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 89: Middle East & Africa - Anaphylaxis Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 90: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 91: Middle East & Africa - Anaphylaxis Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 92: Middle East & Africa - Anaphylaxis Market Attractiveness Analysis, By Distribution Channel, 2025-2035